Skip to main content
. 2019 Jan 3;30(2):355–365. doi: 10.1681/ASN.2018060656

Figure 2.

Figure 2.

Distribution of bone turnover, mineralization and volume at baseline and 12 months in the zoledronate and control study groups. One year after kidney transplant, we observed an increase in low turnover bone disease in both groups. The prevalence of high trabecular volume decreased in the control and zoledronate groups. No significant changes were seen in mineralization. KTx, kidney transplantation.